Device Trial Radar · NCT06041945
Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,800
Planned (sponsor's estimate)
Start
Sep 21, 2023
Primary completion
Sep 1, 2027
Study completion Sep 1, 2027
Sponsor
- Lead sponsor
- Istituto Clinico HumanitasAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 18, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This three parallel-arms, randomized, multicenter trial is aimed at investigating the value of AI-assisted optical biopsy for differentiating between neoplastic and non-neoplastic polyps which will lead to the implementation of cost-saving strategies in screening programs. A cost-effectiveness analyses with the use of modern trial emulation analyses of large observational and clinical trial datasets and real-cost data will be conducted. To improve personalized treatment with a novel colonoscopy CADx risk-prediction tool, the investigators will even develop a novel deep learning algorithm for the optical biopsy of the alternative pathway of colorectal cancer carcinogenesis, namely the serrated pathway and develop cost-effectiveness models of AI-assisted optical biopsy in colorectal cancer screening that provides reliable information to identify cancer risk regardless of physicians' skill.
Conditions
- Colonic Neoplasms
Interventions
Standard, high-definition colonoscopy with the use of CADe assistanceDevice
All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situDevice
All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
Standard, high-definition colonoscopy with the use of CADe/CADx assistance, leave-in-situDevice
Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Non-inferiority in Adenoma Detection RateTime frame: 4 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Istituto Clinico Humanitas
Rozzano, Milano, Italy · Recruiting
Istituto Clinico Humanitas
Rozzano, Milano, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.